ArticleJournal of orthopaedic surgery and research2025
Identification of a novel diagnostic biomarker for osteoarthritis associated with chromatin regulators based on bioinformatics and experiments.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic insights into non-coding RNAs regulate autophagy in chondrocytes and their contribution to osteoarthritis.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is a prevalent chronic degenerative joint disorder characterized by progressive cartilage degradation and extracellular matrix breakdown, yet its precise pathogenesis remains elusive. This study aimed to identify a novel diagnostic biomarker for OA associated with chromatin regulators (CRs) and to explore potential correlations between signature genes and immune cell infiltration.
methodsOA datasets were retrieved from the Gene Expression Omnibus (GEO) database and integrated with a chromatin regulator (CR) dataset. Differential expression analysis was conducted to identify CR-related differentially expressed genes (DEGs), which were subsequently subjected to functional enrichment analysis. Hub genes associated with CRs were identified through protein-protein interaction (PPI) network analysis. Single-sample gene set enrichment analysis (ssGSEA) was then employed to evaluate immune cell infiltration in OA and to assess correlations between hub gene expression and immune infiltration. Potential therapeutic compounds targeting these hub genes were predicted using the Drug Signatures Database (DSigDB). A diagnostic risk model for OA was constructed based on the identified hub genes, and its predictive performance was assessed using receiver operating characteristic (ROC) and calibration curves. Finally, the expression of the signature genes was validated both in vitro and in vivo through quantitative real-time PCR (qRT-PCR), western blotting (WB), and mouse destabilization of the medial meniscus (DMM) models.
resultsA total of 86 CR-related DEGs were identified, primarily enriched in histone binding and modification, the cell cycle, and the FoxO signaling pathway. PPI network analysis revealed 10 hub genes, among which Aurora kinase B (AURKB) was identified as a potential diagnostic biomarker for OA based on the constructed risk model. In mouse DMM models and IL-1β-stimulated chondrocytes, qRT-PCR and western blotting demonstrated significantly elevated AURKB expression in diseased tissues and cells. ssGSEA analysis indicated significant differences in the infiltration levels of 11 immune cell types and 12 immune-related functions between OA and control samples. Furthermore, AURKB expression was positively correlated with tumor-infiltrating lymphocytes (TILs), Th1 cells, T-cell co-inhibition, and immune checkpoint activity. Based on the 10 identified hub genes, dasatinib, enterolactone, and genistein were predicted as potential therapeutic compounds for OA.
conclusionOur findings suggest that AURKB serves as a crucial biomarker in the development and progression of OA and is significantly associated with immune infiltration, offering a novel perspective for elucidating the pathogenesis of OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.